What type of study is this?

This is a Pre-Registered Trial study.

December 8, 2025BloodOpen Access

Frontline treatment of sonrotoclax (BGB-11417) and zanubrutinib for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) demonstrates high undetectable minimal residual disease (uMRD) rates with favorable tolerability: Updated data from BGB-11417-101, an ongoing phase 1/1b study

View Full Paper

Ask AI

Bookmark

Authors

Phase 1/1b trial highlights complete response and undetectable minimal residual disease in CLL patients, indicating excellent tolerability.

Overall response rate was 100% in patients with chronic lymphocytic leukemia, indicating substantial efficacy.
The best undetectable minimal residual disease rate achieved was 94%, with a median follow-up of 27.2 months post treatment.
The combination therapy involved dosing with sonrotoclax and zanubrutinib, monitored for treatment-emergent adverse events.
No disease progression nor clinically significant tumor lysis syndrome occurred during the trial, highlighting treatment safety.

Ghia et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Phase 1/1b trial highlights complete response and undetectable minimal residual disease in CLL patients, indicating excellent tolerability.

Overall response rate was 100% in patients with chronic lymphocytic leukemia, indicating substantial efficacy.
The best undetectable minimal residual disease rate achieved was 94%, with a median follow-up of 27.2 months post treatment.
The combination therapy involved dosing with sonrotoclax and zanubrutinib, monitored for treatment-emergent adverse events.
No disease progression nor clinically significant tumor lysis syndrome occurred during the trial, highlighting treatment safety.

Ghia et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark